Fadlo R. Khuri

84.3k total citations · 6 hit papers
486 papers, 27.1k citations indexed

About

Fadlo R. Khuri is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fadlo R. Khuri has authored 486 papers receiving a total of 27.1k indexed citations (citations by other indexed papers that have themselves been cited), including 242 papers in Molecular Biology, 225 papers in Oncology and 140 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fadlo R. Khuri's work include Lung Cancer Treatments and Mutations (106 papers), Lung Cancer Research Studies (72 papers) and Head and Neck Cancer Studies (61 papers). Fadlo R. Khuri is often cited by papers focused on Lung Cancer Treatments and Mutations (106 papers), Lung Cancer Research Studies (72 papers) and Head and Neck Cancer Studies (61 papers). Fadlo R. Khuri collaborates with scholars based in United States, China and Lebanon. Fadlo R. Khuri's co-authors include Shi‐Yong Sun, Dong M. Shin, Taofeek K. Owonikoko, Ping Yue, Suresh S. Ramalingam, Haian Fu, Waun Ki Hong, J. Jack Lee, Roy S. Herbst and Liu X and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Fadlo R. Khuri

476 papers receiving 26.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

2000 858 citations Fadlo R. Khuri, Waun Ki Hong et al. profile →
Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

2005 682 citations Xuerong Wang, Ping Yue et al. Cancer Research profile →
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

2009 618 citations Taro Hitosugi, Sumin Kang et al. profile →
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

2017 582 citations Gabriel Sica, Zhengjia Chen et al. Proceedings of the National Academy of Sciences profile →
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

2013 486 citations Fadlo R. Khuri, Jonathan J. Beitler et al. profile →
Lung cancer: New biological insights and recent therapeutic advances

2011 391 citations Suresh S. Ramalingam, Taofeek K. Owonikoko et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fadlo R. Khuri United States	85	14.7k	9.9k	5.6k	4.5k	2.7k	486	27.1k
Waun Ki Hong United States	98	16.8k 1.1×	12.7k 1.3×	8.1k 1.4×	5.5k 1.2×	3.8k 1.4×	512	34.0k
Qingyi Wei United States	67	12.7k 0.9×	5.7k 0.6×	2.7k 0.5×	5.7k 1.3×	1.9k 0.7×	552	20.5k
Jennifer R. Grandis United States	75	10.6k 0.7×	10.5k 1.1×	5.0k 0.9×	4.1k 0.9×	989 0.4×	342	23.4k
Scott M. Lippman United States	89	13.5k 0.9×	12.8k 1.3×	10.6k 1.9×	7.9k 1.8×	4.3k 1.6×	528	37.2k
Lillian L. Siu Canada	81	8.2k 0.6×	11.6k 1.2×	6.5k 1.2×	5.0k 1.1×	933 0.3×	579	24.6k
Wilko Weichert Germany	73	8.6k 0.6×	10.1k 1.0×	5.8k 1.0×	5.0k 1.1×	1.2k 0.4×	516	22.1k
Sultan Eser Türkiye	15	7.3k 0.5×	8.6k 0.9×	5.5k 1.0×	4.7k 1.1×	1.0k 0.4×	43	23.4k
Marise Souto Rebelo Brazil	5	7.2k 0.5×	8.2k 0.8×	5.4k 1.0×	4.7k 1.0×	987 0.4×	6	22.7k
Joannie Lortet‐Tieulent France	32	12.8k 0.9×	13.4k 1.3×	9.2k 1.6×	9.0k 2.0×	1.6k 0.6×	47	37.7k
Pierre Hainaut France	84	15.9k 1.1×	12.4k 1.2×	4.1k 0.7×	8.3k 1.8×	2.2k 0.8×	411	30.2k

Countries citing papers authored by Fadlo R. Khuri

Since Specialization

Citations

This map shows the geographic impact of Fadlo R. Khuri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadlo R. Khuri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadlo R. Khuri more than expected).

Fields of papers citing papers by Fadlo R. Khuri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadlo R. Khuri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadlo R. Khuri. The network helps show where Fadlo R. Khuri may publish in the future.

Co-authorship network of co-authors of Fadlo R. Khuri

This figure shows the co-authorship network connecting the top 25 collaborators of Fadlo R. Khuri. A scholar is included among the top collaborators of Fadlo R. Khuri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fadlo R. Khuri. Fadlo R. Khuri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

El‐Rayes, Bassel F., et al.. (2014). Targeted therapies in metastatic esophageal cancer: Advances over the past decade. Critical Reviews in Oncology/Hematology. 91(2). 186–196. 33 indexed citations

Koo, Junghui, Ping Yue, Anthony A. Gal, Fadlo R. Khuri, & Shi‐Yong Sun. (2014). Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth. Cancer Research. 74(9). 2555–2568. 37 indexed citations

Shi, Zhi, Hae Ryoun Park, Yuhong Du, et al.. (2014). Cables1 Complex Couples Survival Signaling to the Cell Death Machinery. Cancer Research. 75(1). 147–158. 33 indexed citations

Zhao, Liqun, Ping Yue, Fadlo R. Khuri, & Shi‐Yong Sun. (2013). mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis. Cancer Research. 73(6). 1946–1957. 35 indexed citations

Shin, Dong M., Hongzheng Zhang, Nabil F. Saba, et al.. (2013). Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies. Clinical Cancer Research. 19(5). 1244–1256. 49 indexed citations

Xie, Maohua, Yun Yen, Taofeek K. Owonikoko, et al.. (2013). Bcl2 Induces DNA Replication Stress by Inhibiting Ribonucleotide Reductase. Cancer Research. 74(1). 212–223. 39 indexed citations

Li, Rui, Zhongliang Hu, Shi‐Yong Sun, et al.. (2013). Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 12(10). 2200–2212. 129 indexed citations

Hildebrandt, Michelle A.T., Scott M. Lippman, Carol J. Etzel, et al.. (2012). Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention. Clinical Cancer Research. 18(13). 3705–3713. 37 indexed citations

Wang, Xu, Ximei Qian, Jonathan J. Beitler, et al.. (2011). Detection of Circulating Tumor Cells in Human Peripheral Blood Using Surface-Enhanced Raman Scattering Nanoparticles. Cancer Research. 71(5). 1526–1532. 292 indexed citations

10.

Yue, Ping, et al.. (2011). Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression. Cancer Research. 71(15). 5245–5254. 42 indexed citations

11.

Chen, Shuzhen, Wei Cao, Ping Yue, et al.. (2011). Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3. Cancer Research. 71(19). 6270–6281. 36 indexed citations

12.

Liu, Yan, Shi‐Yong Sun, Taofeek K. Owonikoko, et al.. (2011). Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells. Molecular Cancer Therapeutics. 11(1). 45–56. 40 indexed citations

13.

Fan, Jun, Taro Hitosugi, Tae‐Wook Chung, et al.. (2011). Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD ⁺ Redox Homeostasis in Cancer Cells. Molecular and Cellular Biology. 31(24). 4938–4950. 188 indexed citations

14.

Wang, Qinhong, Shi‐Yong Sun, Fadlo R. Khuri, Walter J. Curran, & Xingming Deng. (2010). Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax. PLoS ONE. 5(10). e13393–e13393. 27 indexed citations

15.

Wu, Xifeng, Margaret R. Spitz, J. Jack Lee, et al.. (2009). Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants. Cancer Prevention Research. 2(7). 617–624. 44 indexed citations

16.

Zhang, Shumin, Katherine Schafer-Hales, Fadlo R. Khuri, et al.. (2008). The Tumor Suppressor LKB1 Regulates Lung Cancer Cell Polarity by Mediating cdc42 Recruitment and Activity. Cancer Research. 68(3). 740–748. 81 indexed citations

17.

Zhong, Diansheng, Xiuju Liu, Fadlo R. Khuri, et al.. (2008). LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins. Cancer Research. 68(18). 7270–7277. 62 indexed citations

18.

Wang, Xuerong, Ping Yue, Young Ae Kim, et al.. (2008). Enhancing Mammalian Target of Rapamycin (mTOR)–Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation. Cancer Research. 68(18). 7409–7418. 135 indexed citations

19.

Li, Zenggang, Jing Zhao, Yuhong Du, et al.. (2007). Down-regulation of 14-3-3ζ suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proceedings of the National Academy of Sciences. 105(1). 162–167. 128 indexed citations

20.

Marcus, Adam I., Jun Zhou, Aurora O’Brate, et al.. (2005). The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. Cancer Research. 65(9). 3883–3893. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact